Cargando…

Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series

BACKGROUND: Herein, we describe the use of systemic immunotherapy for both locally advanced and metastatic conjunctival melanoma. Current treatments for advanced conjunctival melanoma typically result in poor local control leading to disfiguring orbital exenteration surgery. Locoregional spread of c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Finger, Paul T., Pavlick, Anna C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434860/ https://www.ncbi.nlm.nih.gov/pubmed/30909967 http://dx.doi.org/10.1186/s40425-019-0555-7

Ejemplares similares

The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients
por: Donnelly, Douglas, et al.
Publicado: (2019)

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma
por: Sa, Ho-Seok, et al.
Publicado: (2022)

Tarsoconjunctival flap for scleromalacia related to treatments for conjunctival melanoma
por: Finger, Paul T., et al.
Publicado: (2023)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Conjunctival melanoma
por: de Abreu, Marilda Aparecida Milanez Morgado, et al.
Publicado: (2018)

Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy
por: Chang, Michael, et al.
Publicado: (2019)

TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours
por: Griewank, K G, et al.
Publicado: (2013)

Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management
por: Lomax, Anna J., et al.
Publicado: (2018)

Systemic Treatment of Metastatic Conjunctival Melanoma
por: Pinto Torres, Simão, et al.
Publicado: (2017)

Conjunctival melanoma: a review of conceptual and treatment advances
por: Lim, Li-Anne, et al.
Publicado: (2013)

A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients
por: Russo, Vincenzo, et al.
Publicado: (2011)

Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma
por: Luke, Jason J.
Publicado: (2019)

Synchronous conjunctival melanoma and lentigo maligna melanoma
por: Volpini, Beatrice Mussio Fornazier, et al.
Publicado: (2017)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy
por: DIMITRIOU, Florentia, et al.
Publicado: (2020)

Management Issues in Conjunctival Tumours: Conjunctival Melanoma and Primary Acquired Melanosis
por: Cohen, Victoria M. L., et al.
Publicado: (2019)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Conjunctival Melanoma: A New Clinical and Therapeutical Approach
por: Rodríguez-Martín, M., et al.
Publicado: (2010)

Oncologic and visual outcomes after postoperative proton therapy of localized conjunctival melanomas
por: Thariat, Juliette, et al.
Publicado: (2019)

NF1 mutations in conjunctival melanoma
por: Scholz, S. L., et al.
Publicado: (2018)

Conjunctival melanoma in an African American man
por: Oh, Daniel Jungmyung, et al.
Publicado: (2020)

Genomic and transcriptomic landscape of conjunctival melanoma
por: Cisarova, Katarina, et al.
Publicado: (2020)

5-Hydroxymethylcytosine Loss in Conjunctival Melanoma
por: Stahl, Alexandre, et al.
Publicado: (2021)

Amelanotic conjunctival melanoma in a child
por: Vishnevskia-Dai, Vicktoria, et al.
Publicado: (2022)

Trends in Incidence of Conjunctival Melanoma in the US
por: Weppelmann, Thomas A., et al.
Publicado: (2022)

Conjunctival Melanoma: A Case Presentation
por: Montazer, Fatemeh, et al.
Publicado: (2023)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Conjunctival melanoma copy number alterations and correlation with mutation status, tumor features, and clinical outcome
por: Kenawy, Nihal, et al.
Publicado: (2019)

Advances in immunotherapy for melanoma
por: Redman, Jason M., et al.
Publicado: (2016)

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
por: Kartolo, Adi, et al.
Publicado: (2022)

Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Evaluating the role of human papillomaviruses in conjunctival neoplasia
por: Tornesello, M L, et al.
Publicado: (2006)

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients
por: Peters, Brandilyn A., et al.
Publicado: (2019)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020)

Prognosis of conjunctival melanomas in relation to histopathological features.
por: Fuchs, U., et al.
Publicado: (1989)

Tumour-associated lymphangiogenesis in conjunctival malignant melanoma
por: Zimmermann, P, et al.
Publicado: (2009)

Compound Nevus Simulating a Conjunctival Melanoma
por: Gupta, Parul Chawla, et al.
Publicado: (2018)

β-Catenin Expression and Activation in Conjunctival Melanoma
por: Larivé, Emerentienne, et al.
Publicado: (2019)

Conjunctival Pyogenic Granuloma Masquerading as Malignant Melanoma
por: Rao, Priyanka R, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_acg05gea91rero6a19g8hgjjb6